Ekso Bionics Holdings Q1 2024 GAAP EPS $(0.20) Misses $(0.16) Estimate, Sales $3.756M Miss $4.993M Estimate
Ekso Bionics Holdings Q1 2024 GAAP EPS $(0.20) Misses $(0.16) Estimate, Sales $3.756M Miss $4.993M Estimate
Ekso Bionics Holdings 2024年第一季度GAAP每股收益美元（0.20）未達到預期（0.16）美元，銷售額375.6萬美元未達到49.93萬美元的預期
Ekso Bionics Holdings (NASDAQ:EKSO) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.16) by 25 percent. This is a 39.39 percent increase over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $3.756 million which missed the analyst consensus estimate of $4.993 million by 24.77 percent. This is a 8.88 percent decrease over sales of $4.122 million the same period last year.
Ekso Bionics Holdings（納斯達克股票代碼：EKSO）公佈的季度虧損爲每股0.20美元，比分析師普遍預期的0.16美元（0.16美元）低25％。與去年同期每股虧損0.33美元（0.33美元）相比，增長了39.39％。該公司公佈的季度銷售額爲375.6萬美元，比分析師普遍預期的499.3萬美元低24.77％。這比去年同期的412.2萬美元的銷售額下降了8.88％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。